<PAGE>
===============================================================================

                                  UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION
                             WASHINGTON, D.C. 20549

                                   FORM 10-QSB

[X]   QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE
      ACT OF 1934

                  For the quarterly period ended March 31, 2003

         TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE EXCHANGE ACT

                 For the transition period from ______ to ______


                             LARK TECHNOLOGIES, INC.
        (Exact name of small business issuer as specified in its charter)


           DELAWARE                                            73-1461841
(State or other jurisdiction of                               (IRS Employer
 Incorporation or organization)                             Identification No.)


                 9441 WEST SAM HOUSTON PARKWAY SOUTH, SUITE 103
                                HOUSTON, TX 77099
                    (Address of principal executive offices)

                                 (713) 779-3663
                           (Issuer's telephone number)


Check whether the issuer (1) filed all reports required to be filed by Section
13 or 15(d) of the Exchange Act during the past 12 months (or for such shorter
period that the registrant was required to file such reports), and (2) has been
subject to such filing requirements for the past 90 days. Yes |X| No

                APPLICABLE ONLY TO ISSUER INVOLVED IN BANKRUPTCY
                   PROCEEDINGS DURING THE PRECEDING FIVE YEARS

Check whether the registrant filed all documents and reports required to be
filed by Section 12, 13 or 15(d) of the Exchange Act after the distribution of
securities under a plan confirmed by a court. Yes [ ]  No [ ]

                      APPLICABLE ONLY TO CORPORATE ISSUERS

As of May 5, 2003, there were 3,601,687 shares of Common Stock, par value $0.001
per share, outstanding.

Transitional Small Business Disclosure Format (Check one): Yes [ ]   No  [X]

<PAGE>

                             LARK TECHNOLOGIES, INC.

                              INDEX TO FORM 10-QSB
                      FOR THE QUARTER ENDED MARCH 31, 2003.


Part I   Financial Information (unaudited)

<TABLE>
<CAPTION>
                                                                                            Page
                                                                                            ----
<S>               <C>                                                                       <C>

       Item 1.    Financial Statements

                      Balance Sheet.........................................................    1

                      Statements of Operations..............................................    2

                      Statements of Cash Flows..............................................    3

                      Notes to Financial Statements.........................................    4

       Item 2.    Management's Discussion and Analysis of
                  Financial Condition and Results of Operations.............................    6

       Item 3.  Controls and Procedures.....................................................    8


Part II  Other Information...................................................................   9

       Item 1.    Legal Proceedings..........................................................   9

       Item 2.    Changes in Securities......................................................   9

       Item 3.    Defaults upon Senior Securities............................................   9

       Item 4.    Submission of Matters to a Vote of Security Holders........................   9

       Item 5.    Other Information..........................................................   9

       Item 6.    Exhibits and Reports on Form 8-K...........................................   9

Signatures...................................................................................  10

Certifications...............................................................................  11
</TABLE>


                                       i

<PAGE>

                         PART I - FINANCIAL INFORMATION


ITEM 1. FINANCIAL STATEMENTS


                             LARK TECHNOLOGIES, INC.
                                  BALANCE SHEET

<TABLE>
<CAPTION>
                                                                                          March 31, 2003
                                                                                        --------------------
                                                                                            (Unaudited)
<S>                                                                                     <C>
ASSETS

Current assets:
               Cash and cash equivalents                                                $           853,072
               Accounts receivable (net)                                                          1,294,170
               Due from related parties                                                              67,892
               Inventory                                                                            127,635
               Prepaid expenses                                                                     115,938
                                                                                        -------------------
Total current assets                                                                              2,458,707

Property and equipment, net                                                                       2,133,720
Other assets, net                                                                                    83,587
                                                                                        -------------------
Total assets                                                                                      4,676,014
                                                                                        ===================

Liabilities and stockholders' equity
Current liabilities:
               Accounts payable                                                                     483,924
               Capital lease obligations-current portion                                            518,062
               Accrued expenses                                                                     233,333
               Customer deposits                                                                    243,285
                                                                                        -------------------
Total current liabilities                                                                         1,478,604

Capital lease obligations-long term portion                                                         777,677
Deferred rent expense                                                                                37,197
                                                                                        -------------------
Total Liabilities:                                                                                2,293,478

Stockholders' equity
               Preferred stock, $0.001 par value:
                    Authorized shares - 2,000,000
                    None issued and outstanding
               Common stock, $0.001 par value:
                    Authorized shares - 8,000,000
                    Issued shares:3,684,067 and outstanding shares:3,676,089                          3,684
               Additional paid-in capital                                                         2,819,535
               Treasury Stock at cost                                                               (16,223)
               Deferred compensation                                                                 (4,462)
               Accumulated comprehensive income                                                      10,916
               Accumulated deficit                                                                 (430,914)
                                                                                        -------------------
Total stockholders' equity                                                                        2,382,536
                                                                                        -------------------
                                                                                        -------------------
Total liabilities and stockholders' equity                                                        4,676,014
                                                                                        ===================
</TABLE>

              See accompanying notes to the financial statements.


                                       1

<PAGE>

                             LARK TECHNOLOGIES, INC.
                            STATEMENTS OF OPERATIONS

<TABLE>
<CAPTION>
                                             Three months Ended March 31,
                                          ----------------------------------
                                              2002                2003
                                          ----------------------------------
                                                     (Unaudited)
<S>                                       <C>                 <C>
Revenue:
   Laboratory services                    $   1,480,999       $   2,117,099

Costs and expenses:
   Costs of services                            871,129           1,036,309
   Sales, general and administrative            464,246             608,039
                                          -------------       -------------
Total costs and expenses                      1,335,375           1,644,348
                                          -------------       -------------
Operating income                                145,624             472,751

Other income and (expense):
   Interest income                                1,532               1,583
   Other income                                       -               4,229
   Interest expense                             (18,930)            (23,695)
                                          -------------        -------------
Total other expense                             (17,398)            (17,883)
                                          -------------        -------------
Income before income taxes                      128,226             454,868

Provision for income taxes                       32,000              18,130
                                          -------------        -------------
Net income                                $      96,226        $     436,738
                                          =============        =============

Basic income per common share                      0.03                0.12
                                          =============        =============

Diluted income per common share                    0.03                0.11
                                          =============        =============
</TABLE>

              See accompanying notes to the financial statements.


                                       2

<PAGE>

                             LARK TECHNOLOGIES, INC.
                            STATEMENTS OF CASH FLOWS

<TABLE>
<CAPTION>

                                                                    Three Months ended March 31,
                                                                   -------------------------------
                                                                      2002                2003
                                                                   ------------       ------------
                                                                              (Unaudited)
<S>                                                                <C>                <C>
OPERATING ACTIVITIES
Net income                                                              96,226           $436,738
Adjustments to reconcile net income
   to net cash provided by operating activities
               Depreciation and amortization                           106,852            123,281
               Amortization of deferred compensation                         -                319
               Provision for bad debts                                   4,709              6,176
               Changes in operating assets and liabilities:
                    Accounts receivable                                246,596             20,735
                    Inventory                                           22,081            (79,794)
                    Prepaid expenses and other assets                  (12,612)           (20,879)
                    Due to/from related parties                         (6,827)           (37,194)
                    Accounts payable                                  (115,452)            49,773
                    Accrued expenses                                    20,697              5,027
                    Deferred rent expense                                2,331                  9
                    Customer deposits                                  104,779             (8,380)
                                                                   -----------        -----------
Net cash provided by operating activities                              469,380            495,811

Investing activities
Purchases of property and equipment                                    (61,115)           (95,236)
                                                                   -----------        -----------
Net cash used in investing activities                                  (61,115)           (95,236)

Financing activities
Principal payments on notes payable                                   (161,624)                 -
Principal payments on capital leases                                   (47,080)          (169,189)
Proceeds from exercised stock options                                        -            127,779
                                                                   -----------
                                                                                      -----------
Net cash used in financing activities                                 (208,704)           (41,410)
Effect of currency translation on cash                                      18             (5,224)
                                                                   -----------
                                                                                      -----------
Net increase in cash and cash equivalents                              199,579            353,941
Cash and cash equivalents at beginning of period                       414,242            499,131
                                                                   -----------        -----------
Cash and cash equivalents at end of period                             613,821           $853,072
                                                                   ===========       ===========
</TABLE>

              See accompanying notes to the financial statements.


                                       3

<PAGE>

                             LARK TECHNOLOGIES, INC.
                          NOTES TO FINANCIAL STATEMENTS
                                   (UNAUDITED)


1.       SIGNIFICANT ACCOUNTING POLICIES

Basis of Presentation

         In the opinion of management, the accompanying unaudited interim
financial statements have been prepared in accordance with accounting principles
generally accepted in the United States and the rules and regulations of the
Securities and Exchange Commission. Certain information in footnote disclosures
normally included in financial statements prepared in accordance with accounting
principles generally accepted in the United States have been condensed or
omitted pursuant to these rules and regulations. The accompanying unaudited
interim financial statements reflect all adjustments which the Company considers
necessary for a fair presentation of the results of operations for the interim
periods covered and for the financial condition of the Company at the date of
the interim balance sheet. All such adjustments are of a recurring nature.
Results for the interim periods are not necessarily indicative of results for
the year.

Use of Estimates
         The preparation of financial statements in conformity with accounting
principles generally accepted in the United States requires management to make
judgments, estimates and assumptions that affect the amounts reported in the
financial statements and accompanying notes. Actual results could differ from
those estimates.

Revenue Recognition

         The Company recognizes revenue and related profit upon the completion
and shipment of laboratory service projects. For laboratory service projects
under long-term contracts, revenue and related profit is recognized as specific
projects are completed. Revenues include shipping costs billed to customers and
the related costs are recorded as cost of sales. Costs incurred on partially
completed projects are recorded as work-in-process.

Stock Options

         The Company generally grants stock options to its employees for a fixed
number of shares with an exercise price equal to the fair value of the shares on
the date of grant. As allowed under the Statement of Financial Accounting
Standards No. 123, "Accounting for Stock-Based Compensation" (SFAS 123), the
Company has elected to follow Accounting Principles Board Opinion No. 25,
"Accounting for Stock Issued to Employees" (APB 25) and related interpretations
in accounting for stock awards to employees. Accordingly, no compensation
expense is recognized in the Company's financial statements in connection with
stock options granted to employees with exercise prices not less than fair
value. Deferred compensation for options granted to employees is determined as
the difference between the deemed fair market value of the Company's common
stock on the date options were granted and the exercise price. For purposes of
this pro-forma disclosure, the estimated fair value of the options is assumed to
be amortized to expense over the options' vesting period. Compensation expense
for options granted to non-employees has been determined in accordance with FAS
123 as the fair value of the consideration received or the fair value of the
equity instruments issued.

     Pro forma information under SFAS 123 is as follows (in thousands, except
per share data).


                                       4

<PAGE>

Three Months Ended

<TABLE>
<CAPTION>
                                                                        March 31,
                                                                 2002               2003
                                                             -----------         -----------
<S>                                                          <C>                 <C>
           Net income:
            As reported                                      $    96,226         $   436,738
          Deduct: Total
               stock-based employee
               compensation expense
               determined under fair
               value method for all
               awards, net of related
               tax effects                                      (123,322)           (175,379)
                                                             -----------         -----------

          Pro forma net income (loss)                        $   (27,096)        $   261,359
                                                             ===========         ===========

               Basic net income (loss) per share:
                 As reported                                 $      0.03         $      0.12
                 Pro forma                                   $     (0.01)        $      0.07

               Diluted net income (loss) per share:
                 As reported                                 $      0.03         $      0.11
                 Pro forma                                   $     (0.01)        $      0.07
</TABLE>

The fair value of these options was estimated at the date of grant using the
Black-Scholes option pricing ("Black-Scholes") model for the 2002 and 2003
options granted with the following weighted average assumptions:

<TABLE>
<CAPTION>
                                                             2002                  2003
                                                             ----                  ----
<S>                                                          <C>                   <C>
Volatility                                                    .91                  1.02
Expected dividend yield                                        0%                    0%
Risk-free interest rate                                      3.7%                  3.1%
Expected life (years)                                        5                     5
</TABLE>

2.       INVENTORY

         Inventory is work in process that includes the direct and indirect
costs associated with projects that were started but not yet completed at March
31, 2003. Direct costs include such items as the cost of labor, reagents and
supplies directly associated with each project. Indirect costs include such
items as general supplies, laboratory management, depreciation, and costs to
operate the lab. These costs are applied to each project on the basis of direct
labor hours incurred for the project, up to the point of measurement, such as
the end of an accounting period. At March 31, 2003, work in process inventory
was $127,635.

3.       NOTES PAYABLE

         At March 31, 2003, the Company had a revolving line of credit with a
bank that provided for maximum borrowings of $600,000. Under the terms of the
line, borrowings were to bear interest at the bank's prime rate (4.25% at March
31, 2003) plus 1.5%. The line of credit expired December 31, 2002 and was
renewed through December 31, 2003 with the same terms as the expiring line of
credit. The line of credit is secured by qualified accounts receivable of the
Company. At March 31, 2003, the Company had no amounts outstanding under this
line of credit. The borrowing base for this line of credit is equal to 80% of
certain accounts receivable that are no more than 90 days old. On March 31,
2003, the Company had an available line of credit of $600,000. Under the terms
of the revolving line of credit agreement, the Company is required to maintain
certain financial ratios and a specific level of net worth. The Company was in
compliance with all required covenants at March 31, 2003.


                                       5

<PAGE>

4.       COMPREHENSIVE INCOME (LOSS)

         Accumulated other comprehensive income presented on the accompanying
balance sheets consist of foreign currency translation adjustments. Total
comprehensive income (loss) for the three months ended March 31, 2003 was
$425,446.

5.       EARNINGS PER SHARE

         The following table sets forth the weighted average shares outstanding
for the computation of basic and diluted earnings per share:

<TABLE>
<CAPTION>

                                                        For the three months ending
                                                                 March 31,
                                                          2002               2003
                                                        ---------------------------
<S>                                                     <C>               <C>
Weighted average common shares outstanding:             3,516,898         3,636,372
Dilutive securities - employee stock options:             263,731           225,987
                                                        ---------         ---------
Weighted average common shares outstanding
 Used for dilution:                                     3,780,629         3,862,359
</TABLE>

         In 2002 and 2003, options to purchase 420,940 and 62,500 respectively,
shares of common stock were not included in the computation of diluted EPS,
because the option exercise price was greater than the average market price of
the common shares.

6.       SEGMENT INFORMATION

         The proportion of the Company's revenue by location is as follows for
the periods ended March 31, 2003 and 2002:

<TABLE>
<CAPTION>
                                                 2002                 2003
                                                 ----                 ----
<S>                                            <C>                 <C>
Sales - US                                     $1,104,953          $1,517,074
        UK                                        376,046             600,025
                                               ----------          ----------
                                               $1,480,999          $2,117,099
</TABLE>

7.       SIGNIFICANT AGREEMENT

         On March 20, 2003, the Company entered into a capital lease for the
purchase of a new automated DNA sequencer for the US lab. Under the terms of the
36 months lease, the Company may purchase this equipment for a nominal amount at
the end of the lease.

ITEM 2.  MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION
         AND RESULTS OF OPERATIONS

         The following discussion and analysis should be read in conjunction
with the Financial Statements and the accompanying Notes herein, and is
qualified entirely by the foregoing and by other more detailed financial
information appearing elsewhere.

BUSINESS OF LARK
         Lark is a leader in providing contract molecular biology services to
the pharmaceutical, biotechnology and agbio industries. Lark's services are used
worldwide by research organizations and drug development institutions to
accelerate their efforts in bringing products to the market. Lark's contract
research service portfolio consists of over a hundred different molecular
biology services in the areas of Nucleic Acid Extraction Services, DNA
Sequencing Services, Genetic Stability Testing Services, Gene Expression and
Detection Services, and Custom Molecular Biology Services. A highly trained and
educated scientific staff working in a facility that is compliant with the Food
and Drug Administration's Good Laboratory Practices (CFR Title 21, Part 58)
performs all of these services.


                                       6

<PAGE>

         In 1995 Lark undertook a senescence gene discovery program for its own
account. Although several genes were discovered in this program, lack of gene
functionality coupled with license issues caused Lark to reduce its funding for
this program.

CRITICAL ACCOUNTING POLICIES AND ESTIMATES

         The Company's discussion and analysis of its financial condition and
results of operations are based upon its financial statements, which have been
prepared in accordance with accounting principles generally accepted in the
United States. The preparation of these financial statements requires the
Company to make estimates and judgments that affect the reported amounts of
assets, liabilities, revenues and expenses, and related disclosure of contingent
assets and liabilities. On an on-going basis, the Company evaluates these
estimates, including those related to customer bad debts, estimated useful lives
of property and equipment, and income taxes. The Company bases its estimates on
historical experience and on various other assumptions that are believed to be
reasonable under the circumstances, the results of which form the basis for
making judgments about the carrying values of assets and liabilities that are
not readily apparent from other sources. Actual results may differ from these
estimates.

         The Company believes the following critical accounting policies reflect
the more significant judgments and estimates used in the preparation of the
financial statements:

ALLOWANCE FOR DOUBTFUL ACCOUNTS--The Company maintains an allowance for doubtful
accounts for estimated losses resulting from the inability of our customers to
pay for laboratory service fees. The Company generally requires a deposit of
approximately 50% of the total anticipated billings prior to commencing work on
larger laboratory service projects. Historically, the Company has not
experienced significant bad debts. However, if the financial condition of the
Company's customers were to deteriorate rapidly, resulting in nonpayment, the
Company could be required to provide additional allowances for doubtful accounts
which would decrease net income in the period that this determination was made.

PROPERTY AND EQUIPMENT--Property and equipment relate primarily to laboratory
equipment and computer equipment. These costs are depreciated or amortized over
the estimated useful lives of the assets. If technology related to the
laboratory equipment or computer equipment was to rapidly change, the estimated
useful lives of existing equipment may be shortened. This would result in
accelerating depreciation and amortization expense, which would decrease net
income in the periods following such a determination. Additionally, effective
January 1, 2002, the Company periodically evaluates the costs of property and
equipment for impairment in accordance with Statement of Accounting Standards
No. 144, "Accounting for Impairment or Disposal of Long-Lived Assets." If events
or circumstances were to indicate that any of the long-lived assets might be
impaired, the Company would be required to analyze the estimated undiscounted
future cash flows from the applicable assets. If the carrying value of the asset
were less than the undiscounted cash flows, the Company would be required to
record an impairment loss, which would reduce net income, to the extent that the
carrying value of the asset exceeded fair value.

DEFERRED TAXES--The Company has recorded a valuation allowance to reduce net
deferred tax assets to zero as a result of the Company's cumulative loss
position and the uncertainty of the Company's ability to realize the net
deferred tax assets in the future. If the Company were able to realize the
deferred tax assets in the future, an adjustment to reduce the valuation
allowance would increase net income.

RESULTS OF OPERATIONS

         REVENUES. Revenues increased 43% from $1,480,999 to $2,117,099 for the
three-month periods ended March 31, 2002 and 2003, respectively. The increase in
revenues for the quarter was the result of increased sales of our core
sequencing and genetic stability testing services.

         COSTS OF SERVICES. Costs of services consist primarily of labor and
laboratory supplies. Costs of services increased 19% from $871,129 to $1,036,309
for the three-month periods ended March 31, 2002 and 2003, respectively. The
majority of the increase was a result of increased revenue. Costs of services as
a percentage of revenue were 59% and 49% for the three-month periods ending
March 31, 2002 and 2003.

         SALES, GENERAL AND ADMINISTRATIVE EXPENSES. Sales, general and
administrative expenses consist primarily of salaries and related costs,
depreciation, amortization, legal and professional costs, rent, travel, and
advertising.


                                       7

<PAGE>

Sales, general and administrative expenses increased 31% from $464,246 to
$608,039 for the three-month periods ended March 31, 2002 and 2003,
respectively. The increase resulted mainly from increased number of territory
representatives in the first quarter of 2003 as compared to the first quarter of
2002. Sales, general and administrative expenses as a percentage of revenue were
31% and 29% for the three-month periods ended March 31, 2002

         VARIABILITY OF FUTURE OPERATING RESULTS The growth in quarterly
revenues was largely attributable to increased sales in sequencing services.
Although the Company expects higher and less variable revenue streams resulting
from the implementation of our business strategies, the ultimate success of
these changes cannot be reasonably predicted.

         LIQUIDITY AND CAPITAL RESOURCES. Operating cash flow was $469,380 and
$495,811 for the three-month periods ended March 31, 2002 and 2003,
respectively. The positive operating cash flow for the period ending March 31,
2003 occurred mainly as a result of net income of $436,738.

         On February 28, 2003, the Company renewed its revolving line of credit
through December 31, 2003, and may continue to borrow up to $600,000 under the
terms of the credit line. As of March 31, 2003, there were no amounts
outstanding on this line and the Company was in compliance with all of the
required financial ratios for this facility.

<TABLE>
<CAPTION>

         CONTRACTUAL  OBLIGATIONS AND COMMERCIAL  COMMITMENT--The  following table summarizes the Company's contractual  obligations
 and commercial commitments as of March 31, 2003 and the effect they are expected to have on its liquidity and capital resources:
Contractual                                                    Less than                               After
Obligations                                    Total             1 Year           1-3 Years           3 Years
<S>                                          <C>               <C>              <C>                 <C>
-----------------------------------------------------------------------------------------------------------------
Revolving line of credit                     $           -     $           -    $             -     $           -
Other credit facilities                                  -                 -                  -                 -
Capital lease obligations                        1,412,252           579,451            824,405             8,396
Non-cancelable operating leases                  1,091,043           177,285            329,625           584,133
                                         ------------------------------------------------------------------------
Total contractual obligations                $   2,503,295     $     756,736    $     1,154,030     $     592,529
                                         ========================================================================
Other commercial commitments:
Revolving line of credit availability.        $    600,000     $     600,000    $             -     $           -
                                         ========================================================================
</TABLE>

ITEM 3. CONTROLS AND PROCEDURES

(A)  Evaluation of disclosure controls and procedures

         Based on an evaluation of our disclosure controls and procedures as of
a date within 90 days of the filing date of this Quarterly Report on Form 10-Q,
our Chief Executive Officer and Chief Financial Officer have concluded that our
disclosure controls and procedures (as defined in Rules 13a-14(c) and 15d-14(c)
under the Securities Exchange Act of 1934 (the "Exchange Act")) are effective to
ensure that information required to be disclosed by us in reports that we file
or submit under the Exchange Act is recorded, processed, summarized and reported
within the time periods specified in Securities and Exchange Commission rules
and forms.

(B)  Changes in internal controls

     There have been no significant changes in our internal controls or in other
factors that could significantly affect internal controls subsequent to the date
we carried out this evaluation.


                                       8

<PAGE>

                           PART II - OTHER INFORMATION

ITEM 1.  LEGAL PROCEEDINGS

         None.

ITEM 2.  CHANGES IN SECURITIES

         None.

ITEM 3.  DEFAULTS UPON SENIOR SECURITIES
         None.

ITEM 4.  SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS
         None.

ITEM 5.  OTHER INFORMATION
         None.

ITEM 6.  EXHIBITS AND REPORTS ON FORM 8-K

         No reports on Form 8-K were filed during the quarter ending March 31,
2003.

Index of Exhibits

           2.1(1)   The Agreement of Merger of November 18, 1994,  between Lark
                    Technologies,  Inc. and Lark Sequencing  Technologies, Inc.
                    providing for the merger of Lark Sequencing Technologies,
                    Inc. into the Company.

           3.1(1)   Bylaws of Lark Technologies, Inc., as amended.

           3.2(1)   The Certificate of Incorporation of Lark Technologies, Inc.,
                    as amended.

           4.1(2)   Lark Technologies, Inc. 2000 Stock Option Plan adopted by
                    the Company.

           4.2(3)   Lark Technologies, Inc. 2002 Stock Option Plan adopted by
                    the Company.

           99.1     Certification of Chief Executive Officer and Chief Financial
                    Officer pursuant to 18 U.S.C. Section 1350, as adopted
                    pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

(1)  Incorporated by reference from the Company's Registration Statement on Form
     S-4 dated August 14, 1995, Commission File No. 33-90424. The exhibit
     numbering system used in Form S-4 differed from that used in this Form
     10-QSB (8a, 2d, 2c, 6b, and 6f, respectively).

(2)  Incorporated by reference from the Company's Registration Statement on Form
     S-8 dated September 21, 2000, Commission File No. 333-46280.

(3)  Incorporated by reference from the Company's Quarterly Report on Form
     10-QSB for the quarter ending September 30, 2002 filed November 5, 2002.


                                       9

<PAGE>

SIGNATURES

In accordance with the requirements of the Exchange Act, the registrant caused
this report to be signed on its behalf by the undersigned, thereunto duly
authorized.



                                       Lark Technologies, Inc.
                                            (Registrant)



Date May 14, 2003                       /s/ Carl Balezentis
-----------------                       -------------------------------------
                                        Carl Balezentis
                                        President and Chief Executive Officer


                                       10

<PAGE>

CERTIFICATION

I, Carl W. Balezentis, President and Chief Executive Officer, certify that:

I have reviewed this quarterly report on Form 10-QSB of Lark Technologies, Inc.;

Based on my knowledge, this quarterly report does not contain any untrue
statement of a material fact or omit to state a material fact necessary to make
the statements made, in light of the circumstances under which such statements
were made, not misleading with respect to the period covered by this quarterly
report;

Based on my knowledge, the financial statements, and other financial information
included in this quarterly report, fairly present in all material respects the
financial condition, results of operations and cash flows of the registrant as
of, and for, the periods presented in this quarterly report;

The registrant's other certifying officers and I are responsible for
establishing and maintaining disclosure controls and procedures (as defined in
Exchange Act Rules 13a-14 and 15d-14) for the registrant and have:

         designed such disclosure controls and procedures to ensure that
material information relating to the registrant, including its consolidated
subsidiaries, is made known to us by others within those entities, particularly
during the period in which this quarterly report is being prepared;

         evaluated the effectiveness of the registrant's disclosure controls and
procedures as of a date within 90 days prior to the filing date of this
quarterly report (the "Evaluation Date"); and

         presented in this quarterly report our conclusions about the
effectiveness of the disclosure controls and procedures based on our evaluation
as of the Evaluation Date;

The registrant's other certifying officers and I have disclosed, based on our
most recent evaluation, to the registrant's auditors and the audit committee of
registrant's board of directors (or persons performing the equivalent
functions):

         all significant deficiencies in the design or operation of internal
controls which could adversely affect the registrant's ability to record,
process, summarize and report financial data and have identified for the
registrant's auditors any material weaknesses in internal controls; and

         any fraud, whether or not material, that involves management or other
employees who have a significant role in the registrant's internal controls; and


The registrant's other certifying officers and I have indicated in this
quarterly report whether there were significant changes in internal controls or
in other factors that could significantly affect internal controls subsequent to
the date of our most recent evaluation, including any corrective actions with
regard to significant deficiencies and material weaknesses.



Date May 14, 2003                       /s/ Carl W. Balezentis
-----------------                       ---------------------------------------
                                                Carl W. Balezentis
                                        President and Chief Executive Officer


                                       11

<PAGE>

CERTIFICATION

I, Jon H. Luksich, Controller and Principal Financial Officer, certify that:

I have reviewed this quarterly report on Form 10-QSB of Lark Technologies, Inc.;

Based on my knowledge, this quarterly report does not contain any untrue
statement of a material fact or omit to state a material fact necessary to make
the statements made, in light of the circumstances under which such statements
were made, not misleading with respect to the period covered by this quarterly
report;

Based on my knowledge, the financial statements, and other financial information
included in this quarterly report, fairly present in all material respects the
financial condition, results of operations and cash flows of the registrant as
of, and for, the periods presented in this quarterly report;

The registrant's other certifying officers and I are responsible for
establishing and maintaining disclosure controls and procedures (as defined in
Exchange Act Rules 13a-14 and 15d-14) for the registrant and have:

         designed such disclosure controls and procedures to ensure that
material information relating to the registrant, including its consolidated
subsidiaries, is made known to us by others within those entities, particularly
during the period in which this quarterly report is being prepared;

         evaluated the effectiveness of the registrant's disclosure controls and
procedures as of a date within 90 days prior to the filing date of this
quarterly report (the "Evaluation Date"); and

         presented in this quarterly report our conclusions about the
effectiveness of the disclosure controls and procedures based on our evaluation
as of the Evaluation Date;

The registrant's other certifying officers and I have disclosed, based on our
most recent evaluation, to the registrant's auditors and the audit committee of
registrant's board of directors (or persons performing the equivalent
functions):

         all significant deficiencies in the design or operation of internal
controls which could adversely affect the registrant's ability to record,
process, summarize and report financial data and have identified for the
registrant's auditors any material weaknesses in internal controls; and

         any fraud, whether or not material, that involves management or other
employees who have a significant role in the registrant's internal controls; and


The registrant's other certifying officers and I have indicated in this
quarterly report whether there were significant changes in internal controls or
in other factors that could significantly affect internal controls subsequent to
the date of our most recent evaluation, including any corrective actions with
regard to significant deficiencies and material weaknesses.


Date May 14, 2003                    /s/ Jon H. Luksich
-----------------                    ---------------------------------------
                                                Jon H. Luksich
                                     Controller and principal financial officer


                                       12

<PAGE>

                                INDEX TO EXHIBIT


EXHIBIT NUMBER      DESCRIPTION
--------------      -----------


    2.1(1)          The Agreement of Merger of November 18, 1994,  between Lark
                    Technologies,  Inc. and Lark Sequencing  Technologies, Inc.
                    providing for the merger of Lark Sequencing Technologies,
                    Inc. into the Company.

    3.1(1)          Bylaws of Lark Technologies, Inc., as amended.

    3.2(1)          The Certificate of Incorporation of Lark Technologies, Inc.,
                    as amended.

    4.1(2)          Lark Technologies, Inc. 2000 Stock Option Plan adopted by
                    the Company.

    4.2(3)          Lark Technologies, Inc. 2002 Stock Option Plan adopted by
                    the Company.

    99.1            Certification of Chief Executive Officer and Chief Financial
                    Officer pursuant to 18 U.S.C. Section 1350, as adopted
                    pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.